Scrip
Amgen's Vectibix fails to show survival benefit in pivotal first-line trial in colorectal cancer
05 November 2009
Malini Guha
Amgen's Vectibix (panitumumab) has failed to prolong overall survival in its pivotal Phase III PRIME trial testing the EGFR-targeted human monoclonal antibody as a first-line treatment in advanced colorectal cancer, although a positive trend has been seen.
Median overall survival...
Please Login to read the full article.
05 November 2009
Malini Guha
Median overall survival...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Amgen's Vectibix yields mixed results in second-line Phase III colorectal cancer trial
- Amgen's Vectibix meets goal in pivotal first-line trial in colorectal cancer
- Vectibix clears PFS but survival hurdle still awaits in colorectal cancer
- New US labelling for Erbitux and Vectibix recommends against their use for large subset of colorectal cancerpatients
COMMENT
Other Informa Comment
EVENTS
10 February 2010
London, UK
11 February 2010
London, UK
23 February 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
